Targeted pharmacogenetic-guided treatment improves outcomes in patients with depression
Click Here to Manage Email Alerts
Targeted pharmacogenetic-guided treatment may improve outcomes in patients with depression, according to a study presented at the American Psychiatric Association Annual Meeting.
The pharmacogenomic test used in the study, IDgenetix (Castle Biosciences), incorporates the results of a 15-gene variant panel that includes data on drug-drug interactions and lifestyle factors to provide appropriate medication recommendations.
“Unlike other pharmacogenomic tests, which only consider a patient’s drug-gene interactions, IDgenetix takes into account a patient’s drug-drug interactions and lifestyle factors, and can provide a more comprehensive overview of which medications will be effective therapies for the patient,” Kelly Wosnik, DNP, NP-C, owner and nurse practitioner at Bristol Health, said in a press release.
In a study of 242 patients whose medication management was guided by IDgenetix, participants in the guided group achieved a response rate of 58% and remission rate of 31%, while the unguided group achieved 42% response and 19% remission at 8 weeks.
“As supported by the data in this study, using IDgenetix to guide personalized medication selection can help improve the care of patients suffering from moderate to severe depression by offering hope of improved medication response and remission,” Wosnik said.